Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Clostridium difficile infection (CDI) is a gastrointestinal disease believed to be causally related to perturbations to the intestinal microbiota. When standard treatment has failed, intestinal microbiota transplantation (IMT) is an alternative therapy for patients with CDI. IMT involves infusing intestinal microorganisms (in a suspension of healthy donor stool) into the intestine of a sick patient to restore the microbiota. However, protocols and reported efficacy for IMT vary. We conducted a systematic literature review of IMT treatment for recurrent CDI and pseudomembranous colitis. In 317 patients treated across 27 case series and reports, IMT was highly effective, showing disease resolution in 92% of cases. Effectiveness varied by route of instillation, relationship to stool donor, volume of IMT given, and treatment before infusion. Death and adverse events were uncommon. These findings can guide physicians interested in implementing the procedure until better designed studies are conducted to confirm best practices.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The cure rate is surprisingly up to approximately 90% in recurrent or refractory CDI, which is much superior to prolonged anti-microbial therapy with 20e30% success rates.19,24,25”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [24]
In the citing paper
“Larger volumes of fecal material have shown better FMT outcomes in CDI patients, as demonstrated by a systemic review article, and up to a four-fold higher risk for failure was noted for infusion volumes less than 50 g compared to the larger volume.24”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [24]
In the citing paper
“A systematic review of 325 cases of FMT for CDI suggested a lower success rate for upper gut administration (76%), as compared with colonoscopy (89%) and enema (95%) admini stration [294]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [294]
Citations
Cites
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
(1958) · PubMed · Cited by 978
McFarland, L. V. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510480037031 · Cited by 857
Effect of antimicrobial agents on the ecological balance of human microflora
Sullivan, Å., Edlund, C., & Nord, C. E. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00066-4 · Cited by 818
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R., Gerding, D. N., Nichol, G., Thomas, W. D., Leney, M., Sloan, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907635 · Cited by 746
Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649 · cited 1×
“Various reports have documented changes to the intestinal microbiota after IMT [44, 48, 61], and the microbiota of treated patients typically has been shown to resemble that of the donor after infusion [44, 61].”
BackgroundMicrobiota restoration: natural and supplemented recovery of human microbial communities
Reid, G., Younes, J. A., Van der Mei, H. C., Gloor, G. B., Knight, R., & Busscher, H. J. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2473 · Cited by 588
Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/318130 · Cited by 529
Aas, J., Gessert, C. E., & Bakken, J. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367657 · Cited by 518
BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS
Tvede, M., & Rask-Madsen, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92749-9 · Cited by 491
Research works printed but not linked: 10
- 1998, Clostridium difficile-associated diarrhoea treated with homologous faeces [in Norwegian], Tidsskr Nor Laegeforen, 118, 1027
- 2001, Fecal transplantation via colonoscopy for C. difficile-associated diarrhea: a case series of 6 patients, Gastroenterol, 134, A-671
- 1960, Pseudomembranous enterocolitis: further observations on the value of donor fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis, Am J Proctol, 2, 389
- 1998, Treatment with homologous feces, Tidsskr Nor Laegeforen, 118, 1604
- 2001, Treatment of chronic constipation and colitis using human probiotic infusions
- 1992, Chronic constipation reversed by restoration of bowel flora: a case and a hypothesis, Eur J Gastroenterol Hepatol, 4, 245
- 2010, Metabolic effects of transplanting gut microbiota from lean donors to subjects with metabolic syndrome [presentation 90], 53
- 1996, Recurrent pseudomembranous colitis treated with the donor feces [in Finnish], Duodecim, 112, 1803
- 2007, Fecal bacteriotherapy: an effective treatment for relapsing symptomatic Clostridium difficile infection [abstract G-67]
- 2002, Treatment of recurrent pseudomembranous colitis (RPMC) with stool transplantation: report of 6 cases, Can J Gastroenterol, 16, 43A
Cited by
Diversity, stability and resilience of the human gut microbiota
Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012) · Nature · doi:10.1038/nature11550 · Cited by 5,533
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
A Deep Learning Approach to Antibiotic Discovery
Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.021 · Cited by 2,463
“In cases of recurrent infection, fecal bacteriotherapy is required to re-establish the normal colonic microbiota to outcompete C. difficile (Gough et al., 2011), which can be more invasive than antibiotic therapy.”
BackgroundGut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Current Understanding of Dysbiosis in Disease in Human and Animal Models
DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000750 · Cited by 1,122
“The relationship between the donors and patient does not seem to affect the outcome.(92,93) FMT was originally performed through fecal enemas, subsequently also through nasoduodenal tubes (1991) and colonoscopy administration (2000).”
BackgroundKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Correlation detection strategies in microbial data sets vary widely in sensitivity and precision
Weiss, S., Van Treuren, W., Lozupone, C., Faust, K., Friedman, J., Deng, Y., Xia, L. C., Xu, Z. Z., Ursell, L., Alm, E. J., et al. (2016) · The ISME Journal · doi:10.1038/ismej.2015.235 · Cited by 861
Guinane, C. M., & Cotter, P. D. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13482996 · Cited by 846
Bäckhed, F., Fraser, C. M., Ringel, Y., Sanders, M. E., Sartor, R. B., Sherman, P. M., Versalovic, J., Young, V., & Finlay, B. B. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.10.012 · Cited by 836
Therapeutic Potential of Fecal Microbiota Transplantation
Smits, L. P., Bouter, K. E. C., de Vos, W. M., Borody, T. J., & Nieuwdorp, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.058 · Cited by 717
Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731
Sequencing and beyond: integrating molecular 'omics' for microbial community profiling
Franzosa, E. A., Hsu, T., Sirota-Madi, A., Shafquat, A., Abu-Ali, G., Morgan, X. C., & Huttenhower, C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3451 · Cited by 719
Ott, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695
Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672
Shen, Z.-H., Zhu, C.-X., Quan, Y.-S., Yang, Z.-Y., Wu, S., Luo, W.-W., Tan, B., & Wang, X.-Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i1.5 · Cited by 646
Kelly, C. R., Khoruts, A., Staley, C., Sadowsky, M. J., Abd, M., Alani, M., Bakow, B., Curran, P., McKenney, J., Tisch, A., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0271 · Cited by 613
Intestinal colonization resistance
Lawley, T. D., & Walker, A. W. (2013) · Immunology · doi:10.1111/j.1365-2567.2012.03616.x · Cited by 610
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Cammarota, G., Masucci, L., Ianiro, G., Bibbò, S., Dinoi, G., Costamagna, G., Sanguinetti, M., & Gasbarrini, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13144 · Cited by 558
Clostridium difficile colitis: pathogenesis and host defence
Abt, M. C., McKenney, P. T., & Pamer, E. G. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.108 · Cited by 551
Genomic approaches to studying the human microbiota
Weinstock, G. M. (2012) · Nature · doi:10.1038/nature11553 · Cited by 539
The microbiome in autoimmune diseases
De Luca, F., & Shoenfeld, Y. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13158 · Cited by 510
Fecal microbiota transplantation: in perspective
Gupta, S., Allen-Vercoe, E., & Petrof, E. O. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15607414 · Cited by 481
Sorbara, M. T., & Pamer, E. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00667-9 · Cited by 468
Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review
Bagdasarian, N., Rao, K., & Malani, P. N. (2015) · JAMA · doi:10.1001/jama.2014.17103 · Cited by 451
The microbiome and gynaecological cancer development, prevention and therapy
Łaniewski, P., Ilhan, Z. E., & Herbst-Kralovetz, M. M. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0286-z · Cited by 450
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Meta-analyses of studies of the human microbiota
Lozupone, C. A., Stombaugh, J., Gonzalez, A., Ackermann, G., Wendel, D., Vázquez-Baeza, Y., Jansson, J. K., Gordon, J. I., & Knight, R. (2013) · Genome Research · doi:10.1101/gr.151803.112 · Cited by 424
“…(Wang et al. 2011), disturbances produced by antibiotics (Jakobsson et al. 2010; Dethlefsen and Relman 2011) including Clostridium difficile colitis (Chang et al. 2008; Khoruts et al. 2010; Gough et al. 2011), and other forms of inflammatory bowel diseases (Willing et al. 2010).”
BackgroundWeingarden, A. R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V. M., Sadowsky, M. J., & Khoruts, A. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2013 · Cited by 423
Carey-Ann, B. D., & Carroll, K. C. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-13 · Cited by 423
The role of the bacterial microbiome in lung disease
Dickson, R. P., Erb-Downward, J. R., & Huffnagle, G. B. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/ers.13.24 · Cited by 419
Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens
Pamer, E. G. (2016) · Science · doi:10.1126/science.aad9382 · Cited by 418
The microbiome as a human organ
Baquero, F., & Nombela, C. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03916.x · Cited by 415
Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches
Belizário, J. E., & Napolitano, M. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01050 · Cited by 372
Bacteria from Diverse Habitats Colonize and Compete in the Mouse Gut
Seedorf, H., Griffin, N. W., Ridaura, V. K., Reyes, A., Cheng, J., Rey, F. E., Smith, M. I., Simon, G. M., Scheffrahn, R. H., Woebken, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.008 · Cited by 360
Fecal microbiota transplantation: past, present and future
Aroniadis, O. C., & Brandt, L. J. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a4b3e · Cited by 336
Microbial Biofilms and Chronic Wounds
Omar, A., Wright, J., Schultz, G., Burrell, R., & Nadworny, P. (2017) · Microorganisms · doi:10.3390/microorganisms5010009 · Cited by 348
Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases
Belizário, J. E., Faintuch, J., & Garay-Malpartida, M. (2018) · Mediators of Inflammation · doi:10.1155/2018/2037838 · Cited by 341
“Fecal bacteriotherapy is a clinical procedure, in which a liquid suspension of stool from a human donor (a family member or a disease-free screened donor) is inoculated into gut’s patients to restore gut microbiota in refractory cases of Clostridium difficile colorectal infection after antibiotic therapy [90, 91].”
BackgroundTurroni, F., Ventura, M., Buttó, L. F., Duranti, S., O’Toole, P. W., Motherway, M. O., & van Sinderen, D. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1318-0 · Cited by 336
“Recent studies involving on fecal microbiota transplantation have resulted in a gut microbiota restoration rate to normal homeostasis of more than 90 % [93–96].”
BackgroundAngelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.257 · Cited by 330
Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D. J., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316818 · Cited by 332
Tipping elements in the human intestinal ecosystem
Lahti, L., Salojärvi, J., Salonen, A., Scheffer, M., & de Vos, W. M. (2014) · Nature Communications · doi:10.1038/ncomms5344 · Cited by 325
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives
Choi, H. H., & Cho, Y.-S. (2016) · Clinical Endoscopy · doi:10.5946/ce.2015.117 · Cited by 318
Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A., & Sadowsky, M. J. (2013) · Gut Microbes · doi:10.4161/gmic.23571 · Cited by 315
“In this procedure, fecal material is taken from a healthy donor and introduced into the gastrointestinal tract of the patient via nasogastric tube, enema or colonoscopy.(7-11) Fecal microbiota transplantation (FMT) is becoming a more widely used technology for treatment of recurrent Clostridum difficile infection (cDI…”
MethodSystematic review: faecal microbiota transplantation in the management of inflammatory bowel disease
Anderson, J. L., Edney, R. J., & Whelan, K. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05220.x · Cited by 313
Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100642 · Cited by 300
(2016) · PubMed · Cited by 287
Microbiota-Targeted Therapies: An Ecological Perspective
Lemon, K. P., Armitage, G. C., Relman, D. A., & Fischbach, M. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004183 · Cited by 286
Fecal microbiota transplantation
Vindigni, S. M., & Surawicz, C. M. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.012 · Cited by 283
The Microbiota and Microbiome in Aging: Potential Implications in Health and Age‐Related Diseases
Zapata, H. J., & Quagliarello, V. J. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13310 · Cited by 279
“Manipulation of the fecal microbiota using fecal transplantation from healthy donors is a plausible approach to recurrent disease refractory to repeated antibiotic treatment.(34) A recent randomized trial showed that fecal microbiota transplantation (FMT) was effective in the treatment of recurrent CDI.”
Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions
Borody, T. J., Paramsothy, S., & Agrawal, G. (2013) · Current Gastroenterology Reports · doi:10.1007/s11894-013-0337-1 · Cited by 275
Beneficial modulation of the gut microbiota
Walsh, C. J., Guinane, C. M., O'Toole, P. W., & Cotter, P. D. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.035 · Cited by 274
Metagenomics for pathogen detection in public health
Miller, R. R., Montoya, V., Gardy, J. L., Patrick, D. M., & Tang, P. (2013) · Genome Medicine · doi:10.1186/gm485 · Cited by 272
An overview of fecal microbiota transplantation: techniques, indications, and outcomes
Brandt, L. J., & Aroniadis, O. C. (2013) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.03.1329 · Cited by 258
Clostridium difficile and the microbiota
Seekatz, A. M., & Young, V. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72336 · Cited by 255
“The success rate of FMT is up to 92% in multiply recurrent CDI patients, depending on the protocol used (73).”
MethodBelizário, J. E., & Faintuch, J. (2018) · Experientia Supplementum · doi:10.1007/978-3-319-74932-7_13 · Cited by 255
Kump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829ea325 · Cited by 235
“A single donor stool administration has been used in most protocols for the treatment of recurrent CDI.9,11,12,14 Bennett and Brinkman15 and Borody et al16 used antibiotic pretreatment in their reported patients with UC although studies in mice showed that this may not be necessary for successful colonization of the d…”
MethodFecal microbiota transplantation broadening its application beyond intestinal disorders
Xu, M.-Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.102 · Cited by 231
Drivers and determinants of strain dynamics following fecal microbiota transplantation
Schmidt, T. S. B., Li, S. S., Maistrenko, O. M., Akanni, W., Coelho, L. P., Dolai, S., Fullam, A., Glazek, A. M., Hercog, R., Herrema, H., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01913-0 · Cited by 233
Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., & Ramesh, M. S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ938 · Cited by 197
“Minor and self-limited gastrointestinal symptoms similar to those seen in this study appear to be common [17].”
BackgroundResultFischer, M., Sipe, B. W., Rogers, N. A., Cook, G. K., Robb, B. W., Vuppalanchi, R., & Rex, D. K. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13290 · Cited by 168
How to: establish and run a stool bank
Terveer, E. M., van Beurden, Y. H., Goorhuis, A., Seegers, J. F. M. L., Bauer, M. P., van Nood, E., Dijkgraaf, M. G. W., Mulder, C. J. J., Vandenbroucke-Grauls, C. M. J. E., Verspaget, H. W., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.015 · Cited by 168
Sartelli, M., Di Bella, S., McFarland, L. V., Khanna, S., Furuya-Kanamori, L., Abuzeid, N., Abu-Zidan, F. M., Ansaloni, L., Augustin, G., Bala, M., et al. (2019) · World Journal of Emergency Surgery · doi:10.1186/s13017-019-0228-3 · Cited by 159
Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders
Evrensel, A., & Ceylan, M. E. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.3.231 · Cited by 150
Dubberke, E. R., Lee, C. H., Orenstein, R., Khanna, S., Hecht, G., & Gerding, D. N. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy259 · Cited by 140
Liu, S., Guo, R., Liu, F., Yuan, Q., Yu, Y., & Ren, F. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s243551 · Cited by 130
“5 mL fresh microbiota solution once a day for 2 weeks and was observed for 30 mins after gavage administration.(21)”
MethodTherapeutic faecal microbiota transplantation: current status and future developments
Borody, T. J., Brandt, L. J., & Paramsothy, S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000027 · Cited by 114
Neemann, K., Eichele, D. D., Smith, P. W., Bociek, R., Akhtari, M., & Freifeld, A. (2012) · Transplant Infectious Disease · doi:10.1111/tid.12017 · Cited by 107
“A recent meta-analysis demonstrated that fecal microbiota therapy is safe and effective in recurrent and refractory CDI (30).”
BackgroundCrum-Cianflone, N. F., Sullivan, E., & Ballon-Landa, G. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00820-15 · Cited by 103
Microbiota abnormalities in inflammatory airway diseases — Potential for therapy
Gollwitzer, E. S., & Marsland, B. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.08.002 · Cited by 100
“Whole fecal microbiota transplantation (FMT) has been used over the past 50 years in the treatment of recurrent intestinal infection with Clostridium difficile (Gough et al., 2011).”
BackgroundThe Metabolic and Ecological Interactions of Oxalate-Degrading Bacteria in the Mammalian Gut
Miller, A., & Dearing, D. (2013) · Pathogens · doi:10.3390/pathogens2040636 · Cited by 101
“The deaths were directly attributed to the infection itself [102].”
BackgroundMazzawi, T., Lied, G. A., Sangnes, D. A., El-Salhy, M., Hov, J. R., Gilja, O. H., Hatlebakk, J. G., & Hausken, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194904 · Cited by 92
Fecal microbiota transplantation: facts and controversies
van Nood, E., Speelman, P., Nieuwdorp, M., & Keller, J. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000024 · Cited by 92
“FMTs are used as last resort for patients with recurrent disease, with reported success rates as high as 94% [4].”
BackgroundA Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics
Allen-Vercoe, E., Reid, G., Viner, N., Gloor, G. B., Hota, S., Kim, P., Lee, C., O’Doherty, K. C., Vanner, S. J., Weese, J. S., et al. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/213828 · Cited by 81
“However, a recent systematic review suggests that administration by NJ tube may be inferior to the rectal route (11).”
BackgroundSbahi, H., & Di Palma, J. A. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000087 · Cited by 75
New hope for Parkinson’s disease treatment: Targeting gut microbiota
Fan, H., Sheng, S., & Zhang, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13916 · Cited by 66
Gut microbiota and epilepsy: a systematic review on their relationship and possible therapeutics
Arulsamy, A., Tan, Q. Y., Balasubramaniam, V., O’Brien, T. J., & Shaikh, M. F. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00431 · Cited by 65
Russell, G. H., Kaplan, J. L., Youngster, I., Baril‐Dore, M., Schindelar, L., Hohmann, E., & Winter, H. S. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000283 · Cited by 64
Bakken, J. S., Polgreen, P. M., Beekmann, S. E., Riedo, F. X., & Streit, J. A. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.08.007 · Cited by 63
“These results are consistent with those previously published [7,9,14,15] and support the assertion that FMT can resolve RCDI for patients who have failed conventional therapy.”
ResultThe impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
(2014) · PubMed Central · Cited by 45
Gastrointestinal Microbiota and Their Contribution to Healthy Aging
Mello, A. M., Paroni, G., Daragjati, J., & Pilotto, A. (2016) · Digestive Diseases · doi:10.1159/000443350 · Cited by 40
Microbiome: paediatricians’ perspective
Arora, S., Dewan, P., & Gupta, P. (2015) · Indian Journal of Medical Research · doi:10.4103/0971-5916.171275 · Cited by 39
Aby, E. S., Vaughn, B. P., Enns, E. A., & Rajasingham, R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac207 · Cited by 28
Fecal microbiota transplantation for Clostridium difficile infection: benefits and barriers
Lo Vecchio, A., & Cohen, M. B. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000023 · Cited by 27
Chinese physicians’ perceptions of fecal microbiota transplantation
Ren, R.-R., Sun, G., Yang, Y.-S., Peng, L.-H., Wang, S.-F., Shi, X.-H., Zhao, J.-Q., Ban, Y.-L., Pan, F., Wang, X.-H., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4757 · Cited by 26
Najmi, M., Tran, T., Witt, R. G., & Nelson, K. C. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00810-1 · Cited by 21
Kelly, K. N., & Monson, J. R. T. (2012) · Surgery (Oxford) · doi:10.1016/j.mpsur.2012.10.005 · Cited by 21
An overview of the microbiome and the effects of antibiotics
Taggart, H., & Bergstrom, L. (2014) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2014.05.005 · Cited by 14
“The donor of the feces is usually a relative or partner, but nonrelated individuals can also donate stool, although there is less benefit.(44) It is important that the donor undergo careful screening because many of the same risks of blood donation, such as human immunodeficiency virus or hepatitis infection, could im…”
Background
Metadata
- Authors
- Gough, E., Shaikh, H., & Manges, A. R.
- Affiliations
- McGill University (CA)
- Research Institute of the McGill University Health Centre (CA)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11-15
- Volume
- 53
- Issue
- 10
- Pages
- 994-1002
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2161590746
- Cited by
- 1,003
- References
- 74
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 40 · 2023: 31 · 2022: 58 · 2021: 50 · 2020: 61 · 2019: 76 · 2018: 79 · 2017: 74 · 2016: 110 · 2015: 110 · 2014: 99 · 2013: 121 · 2012: 55
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (94228_1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, pseudomembranous colitis, gut microbiota, route of administration, treatment efficacy, adverse events
- MeSH terms
- Clostridium Infections, Enterocolitis, Pseudomembranous, Feces, Humans, Intestines, Recurrence, Clostridioides difficile, Treatment Outcome, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.